Ritu Lal, Ph.D.
CEO and Co-Founder of GEn1E Lifesciences Inc.
Dr. Ritu Lal is CEO and Co-Founder of GEn1E Lifesciences Inc. The goal for GEn1E is to transform promising research to therapies for unmet medical needs. She has over 20 years of experience in Biotech/Pharma companies.
In her role as a Senior Executive, she has led Preclinical and Clinical Development teams. She has taken compounds from Discovery to Regulatory Approval and has filed more than 15 Investigational New Drug Applications (IND) in disease areas of neurology, inflammation, virology, pain and oncology. Two compounds have received New Drug Application (NDA) approvals from the US FDA and Ministry of Health and Welfare, Japan (Kaletra for the treatment of HIV and Horizant (Regnite in Japan) for Restless Legs Syndrome (RLS) and Post Herpetic Neuralgia (PHN).
Dr. Lal has a doctorate in Pharmaceutical Sciences and Pharmacology from the University of Maryland and a master’s degree in pharmacology from University of Arizona. Dr. Lal has over 60 publications, book chapters and presentations. She has also received a Master’s in Management from Stanford University’s MSx (Sloan) Program.